Showing results (1-10 of 357) with videos related to
Sort By:
Pageof 36
Trends in Pharmacological Sciences|August 1, 1995
Novel dopamine receptors half a decade laterP Sokoloff, J C SchwartzEuropean Journal of Pharmacology|March 19, 1999
Functional potencies of new antiparkinsonian drugs at recombinant human dopamine D1, D2 and D3 receptorsS Perachon, J C Schwartz, P SokoloffEuropean Psychiatry : the Journal of the Association of European Psychiatrists|July 6, 2000
Dopamine D3 receptor agents as potential new medications for drug addictionB Le Foll, J C Schwartz, P SokoloffNature|November 20, 1980
3H-apomorphine labels both dopamine postsynaptic receptors and autoreceptorsP Sokoloff, M P Martres, J C SchwartzNaunyn-Schmiedeberg'S Archives of Pharmacology|February 1, 1984
Dopaminergic binding sites in rat striatal slices and the action of guanyl nucleotidesM P Martres, P Sokoloff, J C SchwartzMolecular Psychiatry|March 1, 2003
Disruption of nicotine conditioning by dopamine D(3) receptor ligandsB Le Foll, J-C Schwartz, P SokoloffThe European Journal of Neuroscience|July 11, 2000
Involvement of the direct striatonigral pathway in levodopa-induced sensitization in 6-hydroxydopamine-lesioned ratsR Bordet, S Ridray, J C Schwartz, et al.Brain Research. Brain Research Reviews|March 17, 2000
Possible implications of the dopamine D(3) receptor in schizophrenia and in antipsychotic drug actionsJ C Schwartz, J Diaz, C Pilon, et al.European Journal of Pharmacology|August 25, 1995
The preferential dopamine D3 receptor ligand, (+)-UH232, is a partial agonistN Griffon, C Pilon, J C Schwartz, et al.Journal of Neurochemistry|February 1, 1992
Effects of dopaminergic transmission interruption on the D2 receptor isoforms in various cerebral tissuesM P Martres, P Sokoloff, B Giros, et al.Pageof 36